{"id":326788,"date":"2022-01-13T01:00:00","date_gmt":"2022-01-13T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/proactive-therapy-with-spray-foam-for-psoriasis-vulgaris-persistently-effective\/"},"modified":"2022-01-13T01:00:00","modified_gmt":"2022-01-13T00:00:00","slug":"proactive-therapy-with-spray-foam-for-psoriasis-vulgaris-persistently-effective","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/proactive-therapy-with-spray-foam-for-psoriasis-vulgaris-persistently-effective\/","title":{"rendered":"Proactive therapy with spray foam for psoriasis vulgaris persistently effective"},"content":{"rendered":"

Proactive management with the foam spray fixed combination of calcipotriol and betamethasone dipropionate resulted in fewer relapses and improved long-term symptom control compared with a reactive treatment strategy with a comparable safety profile. This is the conclusion of the PSO-LONG randomized, vehicle-controlled trial.<\/strong><\/p>\n

<\/p>\n

The objective of the phase III study was to investigate the long-term efficacy and safety of twice-weekly proactive therapy with the fixed combination of calcipotriol 0.005% and betamethasone dipropionate 0.064% as a spray foam compared with reactive therapy for psoriasis vulgaris (Fig. 1)<\/span> [1]. Overall, more days in remission and fewer relapses were achieved under the proactive treatment regimen with the fixed combination.<\/p>\n

 <\/p>\n

\"\"<\/p>\n

 <\/p>\n

Study design<\/h2>\n

In an initial 4-week open-label phase, calcipotriol (Cal)\/betamethasone dipropionate (BD) spray foam (Enstilar\u00ae) was used 1\u00d7 daily in all patients [2]. 545 patients who achieved a Physician’s Global Assessment (PGA) score of 0 (appearance-free) or 1 (near-appearance-free) were eligible to participate in the subsequent 52-week maintenance phase and were randomized 1:1 to the Proactive Management (Cal\/BD spray foam, n=272) or Reactive Management (vehicle spray foam, n=273) study arms, each 2x\/week or as an as-needed therapy 1\u00d7\/day for 4 weeks if relapse occurred.<\/p>\n

 <\/h2>\n

\"\"<\/h2>\n

 <\/h2>\n

Effectiveness endpoints<\/h2>\n

The primary endpoint was time to first relapse. 251 patients (46.1%) completed the 52-week maintenance phase. Proactive use of Cal\/BD spray foam significantly reduced the risk of first relapse by 43% compared with reactive therapy (HR 0.57; 95% CI, 47-69%; p<0.001). The median time to first relapse was 56 days under the proactive regimen and 30 days under reactive therapy. For 50% of patients, the time to first relapse had doubled compared with reactive therapy. Furthermore, proactive use had a positive impact on remission duration. Over the one-year period*, patients in the proactive study arm were in remission an average of 41 days longer than the reactively treated control group (p<0.001) with 37.5 additional treatment days per year. The relapse rate decreased by 46% with proactive treatment with Cal\/BD spray foam (95% CI: 37-54%; p<0.001).<\/p>\n

* Recurrences per exposure year<\/em><\/span>
\n <\/p>\n

Safety data<\/h2>\n

The safety and tolerability profile of proactive Cal\/BD spray foam treatment was favorable throughout the study period. The incidence of adverse events was comparable in both study arms, as were rebound phenomena (6 and 7 rebounds, respectively).  The discontinuation rate due to adverse events was also similar under proactive and reactive therapy (0.7% and 0.4%, respectively). The results of this new study are promising and indicate that proactive management with Enstilar\u00ae spray foam leads to improved long-term control of plaque psoriasis compared to the conventional reactive treatment strategy.<\/p>\n

 <\/p>\n

Literature:<\/p>\n

    \n
  1. Lebwohl M, et al: J Am Acad Dermatol 2021; 84(5): 1269-1277.<\/li>\n
  2. Drug information, www.swissmedicinfo.ch, last accessed 06.11.2021<\/li>\n
  3. Calzavara-Pinton P, et al: Abstract 70, Innovations in Dermatology 2021.<\/li>\n<\/ol>\n

     <\/p>\n

    DERMATOLOGY PRACTICE 2021; 31(6): 26<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Proactive management with the foam spray fixed combination of calcipotriol and betamethasone dipropionate resulted in fewer relapses and improved long-term symptom control compared with a reactive treatment strategy with a…<\/p>\n","protected":false},"author":7,"featured_media":114186,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Fixed combination of calcipotriol and betamethasone dipropionate ","footnotes":""},"category":[11340,11508,11530,11548,11503],"tags":[17742,17740,17746,17737,17739,17763,17753,17782,14032,17773,17759,17042,17768],"powerkit_post_featured":[],"class_list":["post-326788","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dermatology-and-venereology","category-education","category-market-medicine","category-rx-en","category-studies","tag-betamethasone","tag-calcipotriol-en","tag-dipropionate","tag-enstilar-en","tag-fixed-combination","tag-foam-spray","tag-proactive-therapy","tag-pso-long-en","tag-psoriasis-en-2","tag-reactive-treatment-strategy","tag-spray-foam","tag-study","tag-symptom-control","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-02 21:31:48","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":326804,"slug":"traitement-proactif-par-mousse-en-spray-durablement-efficace-contre-le-psoriasis-vulgaire","post_title":"Traitement proactif par mousse en spray durablement efficace contre le psoriasis vulgaire","href":"https:\/\/medizinonline.com\/fr\/traitement-proactif-par-mousse-en-spray-durablement-efficace-contre-le-psoriasis-vulgaire\/"},"it_IT":{"locale":"it_IT","id":326833,"slug":"la-terapia-proattiva-con-schiuma-spray-per-la-psoriasi-vulgaris-rimane-efficace","post_title":"La terapia proattiva con schiuma spray per la psoriasi vulgaris rimane efficace.","href":"https:\/\/medizinonline.com\/it\/la-terapia-proattiva-con-schiuma-spray-per-la-psoriasi-vulgaris-rimane-efficace\/"},"pt_PT":{"locale":"pt_PT","id":326859,"slug":"terapia-proactiva-com-espuma-de-pulverizacao-para-psoriase-vulgaris-persistentemente-eficaz","post_title":"Terapia proactiva com espuma de pulveriza\u00e7\u00e3o para psor\u00edase vulgaris persistentemente eficaz","href":"https:\/\/medizinonline.com\/pt-pt\/terapia-proactiva-com-espuma-de-pulverizacao-para-psoriase-vulgaris-persistentemente-eficaz\/"},"es_ES":{"locale":"es_ES","id":326877,"slug":"la-terapia-proactiva-con-espuma-en-aerosol-para-la-psoriasis-vulgar-sigue-siendo-eficaz","post_title":"La terapia proactiva con espuma en aerosol para la psoriasis vulgar sigue siendo eficaz","href":"https:\/\/medizinonline.com\/es\/la-terapia-proactiva-con-espuma-en-aerosol-para-la-psoriasis-vulgar-sigue-siendo-eficaz\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/326788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=326788"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/326788\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/114186"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=326788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=326788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=326788"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=326788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}